Green Journals

International Approved Journals

Journal Information

Journal Title	Investigational New Drugs
Publisher	Springer
ISSN	0167-6997
E-ISSN	1573-0646
Database	SCOPUS
Domain	Health Sciences, Life Sciences

Classification History

Year	A+	A	B	C
2026		✓	✓	
2025		✓	✓	
2024		✓	✓	
2023		✓	✓	
2021/2022		✓	✓	
2020		✓	✓	
2019		✓	✓	
2018		✓		

Classification: The table above shows all journal classifications recorded for each classification year in the Green Journals database. A journal may have more than one classification in the same year.

Recent Articles

Comparative efficacy of CLDN18.2-directed regimens in advanced gastric/gastroesophageal junction adenocarcinoma: a meta-analysis of single-arm trials
2026-10-8
Authors: Yue Yuan, Hongkai Yan, Qinhang Wu
DOI: 10.1007/s10637-026-01635-x

Parthenolide enhances imatinib activity in gastrointestinal stromal tumor models through stress-associated apoptosis
2026-9-15
Authors: Chuang-Ming Zheng, Longyi Piao, Zhenggen Piao et al.
DOI: 10.1007/s10637-026-01631-1

First-in-human phase I study of DT-9081, a selective EP4 receptor antagonist, in advanced solid tumors
2026-9-14
Authors: Rachel Galot, Zahra Castel-Ajgal, Nuria Kotecki et al.
DOI: 10.1007/s10637-026-01636-w

Qishen Yiqi Dripping Pills ameliorate doxorubicin-induced cardiotoxicity: a study based on bioinformatics and experimental verification
2026-8-28
Authors: Jiangtao Wang, Jian Yu, Dong Cao et al.
DOI: 10.1007/s10637-026-01634-y

Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic cancer treated with gemcitabine and nab-paclitaxel: an exploratory biomarker analysis of the GENESECT study
2026-8-28
Authors: Masahiro Hatori, Daiki Tsuji, Kyoka Nagai et al.
DOI: 10.1007/s10637-026-01632-0

Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer
2026-8-27
Authors: Wenjun Xie, Mengrang Tian, Weike Ma et al.
DOI: 10.1007/s10637-026-01633-z

Novel EGFR tyrosine kinase inhibitors exhibiting intrinsic fluorescence
2026-7-23
Authors: Amelia Kierasińska-Kałka, Adrianna Rutkowska, Jacek Mularski et al.
DOI: 10.1007/s10637-026-01625-z

The novel agent VP79s synergistically enhances venetoclax activity in multiple myeloma cells
2026-7-17
Authors: Yunlong Pei, Jiaxun Wang, Taylor Smith et al.
DOI: 10.1007/s10637-026-01629-9

Characterizing the post-market safety profile of lazertinib: a pharmacovigilance study of the FDA Adverse Events Reporting System Database
2026-7-10
Authors: Connor Frey
DOI: 10.1007/s10637-026-01630-2

A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors
2026-7-7
Authors: Daruka Mahadevan, Jay Parekh, Joseph T. Beck et al.
DOI: 10.1007/s10637-026-01626-y